Plan for PrEP costs and coverage
PrEP is medication for people without HIV who want to reduce their chance of acquiring it. A prevention visit helps choose a product that fits exposure, kidney health, other medicines and daily life.
Coverage review and program applications do not guarantee approval or a zero-dollar visit.
Planning the full cost of PrEP care
Ask about the exact medication and formulation, clinician visits, HIV tests, kidney tests when needed, STI screening and injection administration. Confirm the dispensing pharmacy and whether the injectable is billed through a medical or pharmacy benefit. Assistance for medication may not cover visits or labs, and eligibility rules can differ for uninsured patients, commercial plans and public insurance. Request a plan-specific assessment rather than assuming every PrEP service is free or every insurer is accepted. Keep an existing prevention plan while authorization is pending, and contact the prescriber if a refill or injection date is at risk.
HIV PrEP evaluation and prevention care
PrEP is medication for people without HIV who want to reduce their chance of acquiring it. A prevention visit helps choose a product that fits exposure, kidney health, other medicines and daily life. Options include daily oral emtricitabine/tenofovir and long-acting injections. The products have different eligibility and follow-up requirements. PrEP does not replace testing for other STIs, condoms when useful, or pregnancy prevention.
Eligibility: HIV PrEP evaluation and prevention care
PrEP can be discussed with anyone who requests it, without having to disclose a particular identity or partner history. For oral PrEP, the indicated adult/adolescent weight threshold is 35 kg. Daily F/TDF, including generic Truvada, is used for sexual or injection-related risk in CDC guidance. Descovy, F/TAF, is for sexual risk excluding receptive vaginal sex; that limitation concerns the exposure, not simply someone’s gender identity. Injectable Apretude and Yeztugo are approved for sexual HIV prevention. Each requires confirmed HIV-negative status.
What to expect: HIV PrEP evaluation and prevention care
Review exposure and current protection
Discuss sexual and injection exposures, prior PrEP/PEP, recent missed doses and symptoms. If a potential HIV exposure was within 72 hours, get urgent PEP advice before a routine prevention appointment.
Select tests and a suitable product
Oral PrEP requires kidney assessment and hepatitis B screening. CDC uses estimated creatinine clearance above 60 mL/min for F/TDF initiation and at least 30 mL/min for F/TAF. Descovy also involves lipid and weight monitoring. Injectables have their own HIV testing and interaction checks.
Write the start or switch plan
Agree on the first dose, when protection is expected for your exposure and what to use during a transition. An optional Apretude oral lead-in differs from Yeztugo’s required initiation tablets. Do not transfer one product’s schedule to another.
Arrange follow-up and access
Oral prescriptions are connected to HIV testing at least every three months. Injection follow-up uses the relevant product calendar. Build in STI screening, refills, symptom contact and a backup plan for travel or coverage problems.
Preparing for your appointment
Bring medication and supplement lists, kidney and hepatitis B records, recent HIV tests and dates of prior prevention doses. Ask how results will be reviewed, how long a refill lasts and where injections are administered. Testing may still be needed even if you recently tested elsewhere, because the date, assay and intervening exposures matter. A negative home oral-fluid test alone may be inadequate when recent infection is a concern.
Risks and when to seek help
Both oral formulations carry warnings about resistance during undetected HIV and hepatitis B worsening after stopping in someone with HBV. Hepatitis B does not automatically rule out oral PrEP, but stopping requires coordinated monitoring or treatment. F/TDF can affect kidney function and bone health. Report new symptoms or intolerance rather than abandoning protection without a plan. Your clinician reviews pregnancy and breastfeeding separately for the chosen product.
Follow-up and treatment review
Follow-up assesses HIV status, adherence, exposure, side effects and ongoing preferences. Kidney testing occurs at intervals based on age, baseline function and other risks, with at least annual monitoring for oral PrEP. A missed dose does not have one universal answer across pills and injections. Contact the team if exposure occurred during an interruption, and do not wait for a later HIV test when PEP may still be timely.
Appointments, costs and coverage
Compare total care costs: medication, visits, labs and injection administration. Ask about the exact plan and formulation, authorization, pharmacy and assistance eligibility. Some assistance pays for medication but not all visit or testing costs. Confirm the exact plan terms, medication supply and administration charges with the service. Request a product-specific access assessment and keep the current prevention plan while it is arranged.
Questions about your care
Possible HIV exposure within 72 hours?
Possible HIV exposure is time-sensitive. Seek PEP assessment as soon as possible, ideally within 24 hours and no later than 72 hours after a qualifying exposure. PEP is a 28-day course of antiretroviral medication used after exposure; it is different from ongoing PrEP. Do not wait for symptoms, a partner’s results, insurance approval or a routine appointment. If a clinic cannot assess you promptly, go to an emergency department or another service able to start PEP.
Tell the service the exact date and time, what happened, any prior PrEP doses and what is known about the source. If sexual assault occurred, urgent care can also address injuries, pregnancy prevention, other infections and support; PEP decisions should not wait for reporting or paperwork.
A baseline HIV test and renal, hepatic, hepatitis, STI or pregnancy testing may be needed. When PEP is indicated, the first dose should not be delayed waiting for laboratory results that are unavailable immediately.
Confirm where the medication will be dispensed, how the full 28-day supply will be obtained and whom to call for side effects or a missed dose. The regimen is selected for age, pregnancy, organ function and interactions.
CDC recommends early contact around 24 hours to check access and tolerance, with clinical/laboratory follow-up at 4–6 and 12 weeks after exposure. Your clinician specifies the HIV antigen/antibody and nucleic-acid tests and any timing adjustments.
Is PrEP always free?
PrEP is not automatically free for every patient or for every part of care. Ask the exact insurer and prescribing service about the medicine, visits, laboratory tests and injection administration separately. Assistance programs have eligibility rules and may not cover every component. Request a written estimate and ask about public prevention services if cost is a barrier. A free medicine offer is not proof that the entire care program is free.
Can I use manufacturer copay assistance with any insurance?
No. Manufacturer savings and patient-assistance programs have different current eligibility rules. Ask the exact official program whether your commercial or government insurance, coverage status and prescription qualify, and what it covers. Do not assume a copay offer applies to Medicaid, Medicare, uninsured care or every clinic/laboratory charge. Verify the full care cost separately.
Should cost questions delay PEP after an exposure?
Possible HIV exposure is time-sensitive. Seek PEP assessment as soon as possible, ideally within 24 hours and no later than 72 hours after a qualifying exposure. PEP is a 28-day course of antiretroviral medication used after exposure. It is different from ongoing PrEP. Do not wait for symptoms, a partner’s results, insurance approval or a routine appointment. If a clinic cannot assess you promptly, go to an emergency department or another service able to start PEP.
Medical sources
- CDC clinical guidance for PrEP
- Descovy US prescribing information
- Truvada US prescribing information
- Yeztugo US prescribing information
- CDC injectable lenacapavir PrEP recommendation
- Apretude US prescribing and patient information
- CDC PEP clinical guidance
- CDC HIV testing
- Gilead investigational once-yearly lenacapavir status
- Gilead weekly oral lenacapavir application status
- Cabenuva US prescribing and patient information
- CDC 2025 nonoccupational HIV PEP recommendations
- NYC sexual-health clinics
Start with NYC Health’s PrEP resources and ask the clinic which current assistance pathways may apply. Do not assume Nao participates in every listed program or that an application is approved.
Compare available PrEP pathways · Daily and injectable choices
Choose your PrEP care pathway
Confirm the visit, testing and treatment costs separately with the clinic and your insurer.
Compare PrEP optionsContent was updated September 15, 2026 from the sources cited on the cited resources. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.